Anti-angiogenic cancer vaccinations – a promising future for cancer immunotherapy

In this video, Samuel C. Wagner, President and CEO of Batu Biologics, discusses Facciponte’s study of a TEM-1 DNA vaccination’s efficacy as a cancer therapeutic and the affect of the vaccination on healthy angiogenesis processes in the body.

[iframe url=”” width=”572″ height=”312″]

Watch the video

Awarded Exclusive License from UC San Diego

Batu Biologics Awarded Exclusive License from University of California San Diego for Drug That Stimulates Immune System to Kill Cancer
Biotech Start Up Expands its Oncology Immunotherapeutic Product Pipeline

Productive and beneficial relationships with cutting-edge pharmaceutical companies such as Batu Biologics help speed further development of promising new drugs to those most in need.

Read the full article at